financetom
Business
financetom
/
Business
/
Onto Innovation Q2 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Onto Innovation Q2 revenue beats estimates
Aug 7, 2025 3:08 PM

Overview

* Onto Innovation ( ONTO ) Q2 revenue rises 5% yr/yr, beating analyst expectations

* Adjusted EPS of $1.25 missed analyst estimates, per LSEG data

* Company had acquired Semilab product lines for $545 mln

Outlook

* Onto Innovation ( ONTO ) expects Q3 revenue between $210 mln and $225 mln

* Company forecasts Q3 gross margin of 53% to 55%

* Onto Innovation ( ONTO ) anticipates Q3 non-GAAP EPS of $0.75 to $0.95

* Company sees Q3 as low revenue point, expects Q4 rebound

Result Drivers

* DRAGONFLY EXPANSION - Expanded Dragonfly 3Di metrology footprint with shipments to over 10 customers for various applications

* DEFECT INSPECTION ADOPTION - Strong adoption of sub-surface defect inspection with over 20 Dragonfly systems shipped for AI packaging

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $253.60 $252.30

Revenue mln mln (7

Analysts

)

Q2 Miss $1.25 $1.27 (7

Adjusted Analysts

EPS )

Q2 EPS $0.69

Q2 Net $33.91

Income mln

Q2 Gross 48.2%

Margin

Q2 $32.25

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductor equipment & testing peer group is "buy"

* Wall Street's median 12-month price target for Onto Innovation Inc ( ONTO ) is $140.00, about 35.7% above its August 6 closing price of $90.00

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alexander's Q2 FFO, Revenue Decrease
Alexander's Q2 FFO, Revenue Decrease
Aug 4, 2025
09:17 AM EDT, 08/04/2025 (MT Newswires) -- Alexander's (ALX) reported Q2 funds from operations Monday of $2.88 per diluted share, down from $3.31 a year earlier. A single analyst polled by FactSet expected $2.85. Revenue for the quarter ended June 30 was $51.6 million, down from $53.4 million a year earlier. A single analyst surveyed by FactSet expected $51.9 million....
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
David Ellison to lead combined company after Paramount-Skydance merger closes
David Ellison to lead combined company after Paramount-Skydance merger closes
Aug 4, 2025
Aug 4 (Reuters) - Skydance Media CEO David Ellison will lead the new company as chief executive after its merger with Paramount Global ( PARAA ) is completed by August 7, the independent studio said on Monday. After the deal closes, the company is expected to be structured into three primary business segments - studios, direct-to-consumer and TV media. Ellison...
TransMedics Says US FDA Grants Investigational Device Exemption For Its OCS Heart Trial
TransMedics Says US FDA Grants Investigational Device Exemption For Its OCS Heart Trial
Aug 4, 2025
09:21 AM EDT, 08/04/2025 (MT Newswires) -- TransMedics Group ( TMDX ) said Monday that the US Food and Drug Administration has granted conditional approval for its Investigational Device Exemption, allowing the company to move forward with its next-generation OCS heart trial. The trial is divided into two parts: part A designed to support prolonged heart perfusion using the OCS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved